The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.95
Bid: 33.00
Ask: 33.85
Change: -1.90 (-5.45%)
Spread: 0.85 (2.576%)
Open: 34.25
High: 34.75
Low: 32.95
Prev. Close: 34.85
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Notification of major holdings

2 Dec 2021 12:02

RNS Number : 3900U
Futura Medical PLC
02 December 2021
 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Futura Medical PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify) iii:

 

3. Details of person subject to the notification obligation iv

Name

Lombard Odier Asset Management (Europe) Limited

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.) v

Name

Disclosure on behalf of accounts managed on a discretionary basis by Lombard Odier Investment Managers group.

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached vi:

01/12/2021

6. Date on which issuer notified (DD/MM/YYYY):

02/12/2021

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

25.00%

 

25.00%

71,812,565

Position of previous notification (if

applicable)

24.00%

 

24.00%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB0033278473

 

71,812,565

 

25.00%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

71,812,565

 

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

 

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional information xvi

 

     

 

Place of completion

London, United Kingdom

Date of completion

02/12/2021

 

 

Notes

 

 

i Please note this form should be read jointly with the applicable Disclosure Guidance and Transparency Rules Chapter 5 (DTR5) available on the following link: https://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all parties to the agreement referred to in DTR5.2.1 (a) or (d) the holder of financial instruments referred to in DTR5.3.1.

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in DTR5.2.1 (b), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in DTR5.2.1 (c), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in DTR5.2.1 (d), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in DTR5.2.1 (e), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in DTR5.2.1 (g), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to DTR5.2 unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights held in the issuer shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold, please note that it might not be necessary to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only in this way will the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain by numbering each chain accordingly. Please see the below example:

Name of ultimate controlling person A (chain 1)

Name of controlled undertaking B

Name of controlled undertaking C

Name of ultimate controlling person A (chain 2)

Name of controlled undertaking B

Name of controlled undertaking D

Name of ultimate controlling person A (chain3)

Name of controlled undertaking E

Name of controlled undertaking F

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFIFFFLFIIL
Date   Source Headline
16th Oct 20177:00 amRNSFurther Positive Market Research Data for MED2002
13th Sep 20177:00 amRNSDirectors' / PDMR Dealing and Grant of Options
12th Sep 20177:00 amRNSInterim Results
1st Sep 201712:24 pmRNSNotification of Major Interest in Shares
23rd Aug 201710:32 amRNSCSD500: Termination of Licensing Agreement
22nd Aug 20173:59 pmRNSNotification of Half Year Results
4th Jul 20177:00 amRNSInvestor Presentation on MED2002
14th Jun 20175:00 pmRNSResult of AGM
14th Jun 20177:00 amRNSAGM Statement
31st May 20177:00 amRNSMED2002 Regulatory Update
31st May 20177:00 amRNSTotal Voting Rights
22nd May 20177:00 amRNSBlock Listing Update
20th Apr 20179:45 amRNSNotice of AGM
4th Apr 201712:11 pmRNSNotification of Major Interest in Shares
4th Apr 201712:10 pmRNSNotification of Major Interest in Shares
23rd Mar 20177:00 amRNSPreliminary Results
22nd Mar 20177:00 amRNSLicenses CSD500 in Portugal
6th Mar 20177:00 amRNSResearch Confirms MED2002's US$1 Billion Potential
6th Mar 20177:00 amRNSMED2002 Additional Patent Filing
23rd Jan 20171:00 pmRNSNotice of Preliminary Results
18th Jan 20174:30 pmRNSDirector's dealings
13th Jan 20175:45 pmRNSDirector / PDMR Dealing and Grant of Options
12th Jan 20173:00 pmRNSDirector / PDMR Dealing and Total Voting Rights
11th Jan 201712:20 pmRNSDirector's Dealings
10th Jan 201712:40 pmRNSNED Remuneration and Total Voting Rights
10th Jan 20177:00 amRNSSigns UK Licensing Agreement in Pain Relief
5th Jan 20177:00 amRNSInitial Launch of CSD500 in MENA
28th Nov 20165:30 pmRNSCorrection: Notification of Major Interests
28th Nov 201612:00 pmRNSNotification of Major Interest in Shares
25th Nov 20165:25 pmRNSCorrection - Block Listing Update
25th Nov 20163:05 pmRNSBlock Listing Update
25th Nov 20169:30 amRNSNotification Of Major Interest In Shares
23rd Nov 20163:30 pmRNSNotification of Major Interest in Shares
16th Nov 20167:00 amRNSKen James to lead Futura's R&D
16th Nov 20167:00 amRNSMED2002 Update
15th Nov 20163:38 pmRNSResult of General Meeting
27th Oct 201612:45 pmRNSResult of Placing
27th Oct 20169:48 amRNSClose of Accelerated Bookbuild
27th Oct 20167:01 amRNSProposed Accelerated Bookbuild
27th Oct 20167:00 amRNSCSD500: Approval of TTK with Extended Shelf Life
13th Sep 20167:00 amRNSInterim Results
12th Sep 20165:45 pmRNSNotification of Major Interest in Shares
12th Sep 20163:00 pmRNSNotification of Major Interest in Shares
7th Sep 20167:00 amRNSMED2002: Breakthrough Results in $5 billion Market
25th Jul 20167:00 amRNSNotification of Half Year Results
21st Jun 20165:30 pmRNSResult of AGM
21st Jun 20167:00 amRNSAGM Statement
20th Jun 20167:00 amRNSLicenses CSD500 to Milsing for Southeast Europe
13th Jun 20167:00 amRNSManufacturing and Distribution Agreements with TTK
19th May 20164:30 pmRNSBlock Listing Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.